Prashant Natteru, MD
Neurology · la Crosse, WINPI 1790205078
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Amneal Pharmaceuticals LLC at 41.7% of the total. Reporting peaked in 2023 at $733 and has fallen 85.8% since, to $104 in 2024.
Across 23 payments — averaging $54.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amneal Pharmaceuticals LLC$525
- Jazz Pharmaceuticals Inc.$173
- Abbott$151
- Sanofi$122
- AbbVie$104
- Acorda Therapeutics, Inc$55
- plus $130 from 6 others
What the payments were for
- Consulting fees$52542%
- Speaking & faculty fees$554%
- Food & beverage$68054%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amneal Pharmaceuticals LLC | 1 | $525 |
| Jazz Pharmaceuticals Inc. | 2 | $173 |
| Abbott | 1 | $151 |
| Sanofi | 6 | $122 |
| AbbVie | 1 | $104 |
| Acorda Therapeutics, Inc | 3 | $55 |
| UCB, Inc. | 3 | $40 |
| Genentech USA, Inc. | 2 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| SK Life Science, Inc. | 1 | $14 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,260 in reported general payments places this provider in the 70th percentile of 308 neurology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $112,723 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 524 | $16,004 |
| Lamotrigine ErLamotrigine | 11 | $8,039 |
| Tetrabenazine | 11 | $7,232 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 225 | $6,655 |
| Levetiracetam | 79 | $2,676 |
| AmantadineAmantadine Hcl | 29 | $1,781 |
| Lamotrigine | 82 | $1,645 |
| Levocarnitine | 11 | $1,073 |
| Oxcarbazepine | 26 | $848 |
| Lacosamide | 11 | $612 |
| Primidone | 52 | $608 |
| Topiramate | 38 | $601 |
| Divalproex Sodium ErDivalproex Sodium | 17 | $588 |
| Divalproex Sodium | 29 | $449 |
Paid to pharmacies, not to this prescriber.
Other neurology in la Crosse
- Michael Yangla Crosse$153K
- Paul Spanella Crosse$23K
- Michael Doerrlerla Crosse$9K
- Smathorn Thakolwiboonla Crosse$4K
- Bhupendra KhatriMilwaukee$2.5M
- Ahmed ObeidatMilwaukee$1.9M
- Staley BrodMilwaukee$1M
- Daniel LongNeenah$899K
- Traci PurathBurlington$524K
- Ashley HoldridgeWhitefish Bay$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.